Last Updated: 02/12/2024
Antibody (Ab) dynamics and organ-chip approaches to test mechanisms of protective antibodies (Abs)
Objectives
To test whether Organ-on-a-Chip technology can inform how antibodies protect humans from pathogen infections to design more effective vaccines.
Identifying protective vaccine features and validating them in human clinical trials is time-consuming and costly. An alternative is to use primary human organ chips that reproduce human physiology in vitro. They will stimulate peripheral blood mononuclear cells on the human lymph-node-on-a-chip with existing COVID vaccines and extensively characterize the resultant antibodies, including evaluating epitope specificity, and isotype and glycan profiling. They will also assess the capacity of these antibodies to prevent or reduce SARS-CoV-2 infection using the lung-on-a-chip technology. This approach can ultimately be applied to other pathogens, such as those causing malaria.
Oct 2023 — Dec 2024
$200,000
Related Resources
